Brooks Cash from the University of South Alabama Health System: Determining Safety and Efficacy in New IBS Treatment

The development of new medications for any condition requires attention to detail in a number of areas, especially safety and efficacy. A recent drug developed for irritable bowel syndrome (IBS) looked to be effective in both areas prior to its approval.

Brooks D. Cash, MD, from the University of South Alabama Health System discussed a study of eluxadoline, which is one of the newest medications approved to treat the condition. Cash, speaking at the annual Digestive Disease Week (DDW) 2016 meeting in San Diego, California, said the study looked particularly at safety effects in regards to hepatobiliary and pancreatic adverse events of the medication.

Also on MD Magazine >>> More news from Digestive Disease Week 2016